Navigation

2007/006 NICE publishes final guidance on bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

The National Institute for Health and Care Excellence (NICE) has today published final guidance on the use of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

The guidance does not recommend the use of these drugs for first line therapy for metastatic colorectal cancer (bevacizumab) and therapy following the failure of an irinotecan containing chemotherapy regimen (cetuximab) and means that the joint appeal against the recommendations contained in the Final Appraisal Determination in respect of cetuximab by Bowel Cancer UK and Cancerbackup and the appeal by Merck Pharmaceuticals have not been upheld.

 

This page was last updated: 30 April 2009

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.